Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3800865 | 0.88 | MAPT (0.54) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL3801076 | 0.87 | MAPT (0.45) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| Hydrochloric Acid SCHEMBL3792949 | 0.87 | MAPT (0.53) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL3803951 | 0.82 | MAPT (0.47) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL14086931 | 0.82 | MAPT (0.54) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL3793464 | 0.82 | MAPT (0.47) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL3803929 | 0.81 | MAPT (0.43) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL3802381 | 0.79 | MAPT (0.45) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL5335832 | 0.78 | MAPT (0.46) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL14276300 | 0.75 | ALDH1A1 (0.41) | MAPTALDH1A1KDM4EPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714137-B2 | 2,2-Dichloro-N-[2-[3-(2-chloro-6-fluorophenyl)-5-isoxazolyl]-(4-pyridyl)]Acetamide; Hepatitis C virus | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080171871-A1 | Pyridyl Substituted Heterocycles Useful For Treating Or Preventing HCV Infection | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-7157473-B2 | Pyridyl substituted heterocycles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040127497-A1 | Pyridyl substituted heterocycles useful for treating or preventing HCV infection | MIDCAP FINANCIAL TRUST | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127497-A1 | Pyridyl substituted heterocycles useful for treating or preventing HCV infection | HAVCR2, HCCS, NQO1 | KDR 2679/4885MAPT 4676/4885ALDH1A1 367/4885 |
| US-20080171871-A1 | Pyridyl Substituted Heterocycles Useful For Treating Or Preventing HCV Infection | HAVCR2, HCCS, NQO1 | KDR 2679/4885MAPT 4676/4885ALDH1A1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.